secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0000059478-23-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q4 2022 EPS $2.14; revenue down 9%; core up 5%; 2023 guidance $7.90-$8.10
-------------------------------------------------------------------------------

- Q4 2022 revenue $7.30B (-9% YoY); ex-COVID antibodies revenue +5% (+10% constant currency).
- Reported EPS $2.14 (+13%); non-GAAP EPS $2.09 (-4%); includes $0.23 acquired IPR&D charges.
- Key growth products (Verzenio, Mounjaro, Jardiance, Taltz, Trulicity, etc.) grew 21% to 70% of revenue.
- 2023 EPS guidance: reported $7.90-$8.10; non-GAAP $8.35-$8.55; mid-teen core revenue growth expected.
- Pipeline: FDA approved Jaypirca for MCL; rolling submission tirzepatide in obesity; Jardiance CKD submissions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/0000059478-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/lly-20230202.htm
  HTML page:      https://secwatch.observer/filing/0000059478-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer